Surgical resection is feasible in a small proportion of patients with oligometastatic renal cell
carcinoma (mRCC) involving the liver or pancreas. The aim of this study was to evaluate the …

The success of targeted therapies, including inhibitors of the vascular endothelial growth
factor pathway or the mammalian target of rapamycin, in the treatment of metastatic renal …

Background Only a few recent phase III trials with targeted therapies or immune checkpoint
inhibitors (ICIs) in metastatic clear-cell renal cell carcinoma (m-ccRCC) demonstrated an …

Abstract Background Immuno-oncology (IO)–based therapies have been approved based
on randomised clinical trials, yet a significant proportion of real-world patients are not …

Background One of the main challenges in the management of renal cell carcinoma (RCC)
is risk-stratifying patients who present with metastatic disease. Tumor size is an important …

Background Vascular endothelial growth factor (VEGF), tyrosine kinase (TK) and
mechanistic target of rapamycin kinase (mTOR) inhibitors are common first-line (1 L) …

Simple Summary Metastatic renal cell carcinoma (mRCC) accounts for one-third of all newly
diagnosed renal cell cancers. A better understanding of the biology and molecular basis of …

Background Screening for renal cell carcinoma (RCC) has been identified as a key research
priority; however, no randomised control trials have been performed. Value of information …

Background This retrospective study investigated overall survival (OS) and factors
influencing OS in Swedish patients with metastatic renal cell carcinoma (mRCC) during the …

Aim: This study was conducted to evaluate the efficacy of surgical treatment for metastases
accompanied by modern targeted therapies and to evaluate the performance of the Leuven …